Navigation Links
Digirad Corporation Reports Financial Results for First-Quarter 2008
Date:4/24/2008

e U.S. Securities and Exchange Commission, including Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.

Investor Contact: Company Contact:

Dan Matsui Todd Clyde, CFO

Allen & Caron 858-726-1600

949-474-4300 ir@digirad.com

Digirad Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended

March 31,

2008 2007

Revenues:

DIS $13,854 $12,197

Product 4,417 5,341

Total revenues 18,271 17,538

Cost of revenues:

DIS 10,912 8,938

Product 2,946 3,158

Total cost or revenues 13,858 12,096

Gross profit 4,413 5,442

Operating expenses:

Research and development 644 782

Sales and marketing 2,119 2,098

General and administrative 3,159 2,972

Amort
'/>"/>

SOURCE Digirad Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Digirad Corporation to Release First Quarter Financial Results on April 24, 2008
2. Digirad Corporation Appoints John W. Sayward to Its Board of Directors
3. Digirad Corporation to Release Fourth Quarter, Year-End Financial Results on February 7, 2008
4. Digirad to Introduce New Clinical Standard for Cardiac SPECT
5. Digirad Corporation Board of Directors Appoints R. King Nelson Chairman
6. Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement
7. Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results
8. Digirad Corporation Named to Deloitte Technology Fast 50
9. Digirad Corporation to Release Third Quarter, Nine-Month Financial Results on October 25, 2007
10. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
11. STERIS Corporation Declares Regular Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 29, 2015 Designed with ... teamed up to create an all new, exclusive line ... a formulated with the latest and greatest, high impact, ... proven to be effective. The 24/7 Series can be ... cross-fitters and even the casual fitness enthusiasts. There are ...
(Date:5/29/2015)... The annual aesthetic meeting, put on by the American Society ... May 14-19th. This global event sets a gold standard ... dedicating itself exclusively to cosmetic medicine. Dr. Paul Vitenas ... to attend this year’s meeting. , Among the classes and ... the honor of sitting at the presenter’s table during a ...
(Date:5/29/2015)... 2015 The report “Axillary ... comprehensive information on the therapeutic development for ... by identifying new targets and MOAs to ... on H1 2015 pipeline review of Axillary ... 13 figures, spread across 47 pages is ...
(Date:5/29/2015)... 29, 2015 External Counterpulsation, also known as ... treatment for patients. The Heart Fit Clinic is the first ... a raving review from patients who are now completing treatment. ... underwent 35 treatments of ECP treatment and received great results. ... Not only does the clinic perform this non-surgical treatment for ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 DISC, a ... personality type and behavior, is used by companies to ... productivity. What was once considered an out-of-the-box practice, has ... A recent poll from the Society for Human Resource ... personality assessments like DISC to be an essential part ...
Breaking Medicine News(10 mins):Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2Health News:PeopleKeys to Air a Follow-up to Their Popular DISC Trainer’s Toolbox Webinar, Featuring All-New Content and Strategies 2
... TUESDAY, Jan. 25 (HealthDay News) -- It,s hard to help ... long-term is even tougher. But obese children whose parents took ... weight and kept it off for the next two years, ... study shows that targeting parents -- rather than the children ...
... a friendly bartender can be the source of more than ... suggests that some bartenders may be in a good position ... help connect them to the appropriate agency. Researchers at ... Foreign Wars posts in Ohio. The results showed that ...
... Colo. (Jan. 25, 2011) A new study led ... at The Children,s Hospital and Colorado Health Outcomes Program ... explores the barriers, facilitators and alternative approaches to providers ... immunization registry. Reminder or recall messages, usually in the ...
... by further developing a culture of safety in which all ... can work together to maximize safety, according to an invited ... (PRO), a new medical journal whose mission is to ... official journal of the American Society for Radiation Oncology (ASTRO). ...
... 25 (HealthDay News) -- Epilepsy was the likely cause of ... to a new study. Researchers reached the conclusion that ... descriptions of his hallucinations -- including his description of a ... life written by pupils and friends such as George Sand. ...
... cardiovascular surgery, resulting in elevated circulating levels of cell-free ... and gut wall integrity is unclear. A research ... the World Journal of Gastroenterology addresses this ... levels similar to those found during cardiovascular surgery. The ...
Cached Medicine News:Health News:Changing Parental Behavior May Help Obese Kids Lose Weight 2Health News:Changing Parental Behavior May Help Obese Kids Lose Weight 3Health News:Bartenders may have role in assisting troubled war veterans 2Health News:Bartenders may have role in assisting troubled war veterans 3Health News:New study finds reminders for immunizations challenging for pediatric practices 2Health News:New study finds reminders for immunizations challenging for pediatric practices 3Health News:Culture of safety key to reducing chances for medical errors 2
(Date:5/29/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... at the American Association of Cancer Research ... on the potential for its lead product candidate ...
(Date:5/29/2015)... OAKS, Calif. , May 29, 2015 /PRNewswire/ ... pooled data from two pivotal Phase 3, global, ... calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) ... hemodialysis. Both studies met the primary endpoint, demonstrating ... AMG 416 groups achieved a greater than 30 ...
(Date:5/28/2015)... -- Eli Lilly and Company (NYSE: LLY ) announced today ... for up to $1.6 billion aggregate principal amount of certain ... who tendered, and did not validly withdraw, their notes on ... time, on May 27, 2015 (the early tender date), ... to receive the total consideration. The total consideration for each ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... AMSTERDAM, December 8 Biopharmaceutical company Kiadis,Pharma announces ... (FDA) has,granted its product Reviroc(TM) Orphan Drug Designations ... Lymphoma (NHL). One ODD has been,granted for diffuse ... the treatment,of follicular lymphoma. Reviroc(TM) is under development ...
... (Nasdaq:, MEDX ) announced today results from ... of MDX-060 that targets CD30, a,marker for activated ... of,Hodgkin,s lymphoma (HL) as well as other CD30-expressing ... efficacy in cell lines when,compared to MDX-060. The ...
Cached Medicine Technology:Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA 2Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 2Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 3
Segment stand magnifiers come complete with bar magnifier to achieve a higher magnification while still maintaining a wide binocular field of view....
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
... This Illuminated Stand Magnifier offers versatility ... Both the lens and the light ... and small hand held objects can ... the lens parallel to the work ...
Contour design eyelid implants....
Medicine Products: